Every 8-K that Guardant Health, Inc. (GH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GH filings page.
Guardant Health reported second-quarter 2026 revenue of $335.0 million, up 44% year over year, led by oncology revenue of $219.1 million and screening revenue of $52.9 million, which grew over 250%. Total oncology tests reached about 104,000, while Shield screening tests increased to about 66,000. Non-GAAP gross margin improved to 67%.
GAAP net loss widened to $120.1 million (‑$0.90 per share), with non-GAAP net loss of $56.2 million and free cash flow of ‑$69.5 million. Cash, cash equivalents and restricted cash were $1.2 billion as of June 30, 2026.
The company raised full‑year 2026 revenue guidance to $1.34–$1.36 billion, implying 36%–38% growth, with higher expected oncology and Shield volumes. Recent milestones include multiple FDA approvals for Guardant360 assays, Shield’s inclusion in American Cancer Society colorectal screening guidelines, and initial commercial coverage for Shield from UnitedHealth Group.
Guardant Health, Inc. reported results of its June 17, 2026 annual stockholder meeting. Stockholders elected all director nominees, including Ian Clark with 70,526,891 votes for and Manuel Hidalgo Medina with 81,925,123 votes for, with broker non-votes recorded on each.
Stockholders approved the ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 115,899,030 votes for. An advisory vote to approve compensation of named executive officers was not approved, receiving 98,236,639 votes for and 9,905,190 votes against. In an advisory vote on the frequency of future say-on-pay votes, most votes were cast for one year, with 107,997,996 votes for that option.
Guardant Health reported strong first-quarter 2026 growth and raised its full-year 2026 revenue guidance to $1.30–$1.32 billion, implying 32%–34% growth over 2025. Revenue for the quarter rose 48% to $301.7 million, led by oncology revenue of $205.0 million, screening revenue of $41.6 million, and biopharma and data revenue of $53.0 million.
Non-GAAP gross margin improved to 66%, while non-GAAP operating expenses rose to $268.1 million as the company invested in commercial expansion, particularly for its Shield screening business. Guardant remained loss-making, with GAAP net loss of $112.1 million and non-GAAP net loss of $58.7 million, and free cash flow of negative $71.2 million.
The company now expects screening revenue of $186–$198 million in 2026, driven by 230,000–245,000 Shield tests, and continues to target full-year non-GAAP gross margin of 64%–65% and free cash flow burn of $185–$195 million, better than 2025. Cash, cash equivalents, restricted cash and marketable securities totaled about $1.2 billion as of March 31, 2026.
Guardant Health, Inc. disclosed that its Chief Medical Officer, Craig Eagle, M.D., has resigned. His resignation is scheduled to take effect on May 8, 2026. The company reported this leadership change in a current report signed by its Chief Legal Officer and Corporate Secretary, John G. Saia.
Guardant Health, Inc. reported strong growth for the fourth quarter and full year 2025 while still operating at a sizeable loss. Fourth quarter revenue rose 39% to $281.3 million, with Oncology revenue up 30% to $189.9 million and Screening revenue reaching $35.1 million on about 38,000 Shield tests. Non-GAAP gross margin improved to 66%.
For 2025 as a whole, revenue grew 33% to $982.0 million, driven by Oncology revenue of $683.6 million and Screening revenue of $79.7 million on roughly 87,000 Shield tests. Non-GAAP gross margin increased to 66%, but the company recorded a GAAP net loss of $416.3 million, or $3.32 per share, and a non-GAAP net loss of $228.1 million.
Free cash flow burn improved to $233.1 million from $274.9 million. For 2026, Guardant Health expects revenue between $1.25 billion and $1.28 billion, representing growth of 27% to 30%, with continued expansion in Oncology, Biopharma & Data, and a sharp increase in Screening revenue and test volumes.
Guardant Health, Inc. reported that on January 11, 2026 it announced certain preliminary unaudited financial information for the quarter and full year ended December 31, 2025. This information is provided in a press release that is furnished as Exhibit 99.1 to the report, rather than being formally filed, which limits how it is incorporated into other regulatory documents.
The company also disclosed that it will post the investor presentation used at the 2026 J.P. Morgan Healthcare Conference, scheduled for January 12, 2026, on its website under the Investors section. These updates are intended to give the market an early view of recent performance and the materials being shared with investors.
Guardant Health completed two financings. It sold 3,833,332 shares of common stock at $90.00 per share, including the full 499,999-share option, for net proceeds of approximately $327.2 million after underwriting discounts and expenses. The equity sale was made off an effective shelf and closed on November 7, 2025.
Separately, the company issued $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due May 15, 2033, including the full $52.5 million option. Net proceeds were approximately $390.0 million. The notes carry no regular interest, are unsecured, and are convertible at an initial rate of 8.2305 shares per $1,000 (initial conversion price about $121.50 per share), a premium of about 35% to the equity offering price. Conversion is permitted upon specified stock price, trading price, redemption, corporate event triggers, and generally from February 15, 2033 until just before maturity. The company may redeem the notes beginning November 20, 2029 if stock price conditions are met. Guardant expects to use combined proceeds for general corporate purposes, which may include repurchasing a portion of its 2027 notes.
Guardant Health, Inc. furnished an update on its latest results by submitting a Form 8-K. On October 29, 2025, the company issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025, and attached the full text of that release as Exhibit 99.1. The disclosure clarifies that this information, including the exhibit, is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal purposes.
Guardant Health, Inc. announced that it will host an Investor Day on September 24, 2025, beginning at 9:00 a.m. Eastern time in New York City. The event will feature presentations by co-Chief Executive Officers Helmy Eltoukhy and AmirAli Talasaz, along with other executive leaders.
The company plans to highlight its operations and provide updates on key strategic priorities and financial outlook. A live and archived webcast of the presentation will be available through the Investors section of Guardant Health’s website, allowing both in-person and remote participants to follow the event.
Guardant Health, Inc. announced that its Board of Directors increased its size to 11 members and appointed Alex M. Azar II, former United States Secretary of Health and Human Services, as a Class III director effective September 12, 2025. His term will run until the 2027 Annual Meeting of Stockholders and until a successor is elected and qualified, or earlier death, resignation or removal.
Secretary Azar will serve on the Board’s nominating and corporate governance committee. As a non-employee director, he will receive standard compensation under Guardant Health’s Amended Non-Employee Director Compensation Program, including a stock option award and a restricted stock unit award, each valued at $362,500. Each award will vest one-fourth on the first anniversary of his appointment and the remainder in monthly installments over the following three years, subject to continued service. The company will also enter into its standard indemnification agreement with him, and disclosed that there are no related-party arrangements or transactions requiring reporting.